Sanofi Pasteur Closes Emergent Acquisition of Smallpox Vaccine

Oct 6, 2017

Sanofi Pasteur confirms that it has sold its ACAM2000® Smallpox Vaccine, Live assets, which include the Canton, MA and Rockville, MD facilities where the product is manufactured to Emergent. Emergent will assume responsibilities for the manufacturing of ACAM2000® Smallpox Vaccine, Live product. In addition, Emergent has offered employment to all Canton and Rockville employees.

The decision to divest ACAM2000 aligns with Sanofi Pasteur’s strategic focus to concentrate its efforts on addressing public health needs related to current and developing infectious diseases. This decision also sees that a potentially critical public health need continues to be met through Emergent’s team of experts, who work to develop, manufacture and deliver a portfolio of medical counter-measures for biological and chemical threats.

Financial information associated with this divestment was disclosed publicly in Emergent’s press release dated July 14, 2017.